Related Experiment Video

Updated: Jun 10, 2026

Rapid Detection of Bacterial Pathogens Causing Lower Respiratory Tract Infections via Microfluidic-Chip-Based Loop-Mediated Isothermal Amplification
06:11

Rapid Detection of Bacterial Pathogens Causing Lower Respiratory Tract Infections via Microfluidic-Chip-Based Loop-Mediated Isothermal Amplification

Published on: March 29, 2024

Respiratory infections due to drug-resistant bacteria

Jae-Hoon Song1, Doo Ryeon Chung

  • 1Division of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, 135-710, Korea. songjh@skku.edu

Infectious Disease Clinics of North America
|August 3, 2010
PubMed

Insights

Pneumonia, a leading cause of death, is increasingly difficult to treat due to rising antimicrobial resistance in key respiratory pathogens. This resistance complicates therapy and worsens patient outcomes, especially with pandrug-resistant bacteria.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Public Health

Background:

  • Pneumonia is a primary cause of mortality globally.
  • Antimicrobial resistance (AMR) in respiratory pathogens like Streptococcus pneumoniae, Staphylococcus aureus, and gram-negative bacteria is a growing concern.
  • Multidrug-resistant (MDR) and pandrug-resistant (PDR) bacterial infections complicate treatment and lead to poorer clinical outcomes.

Purpose of the Study:

  • To highlight the critical challenge posed by antimicrobial resistance in pneumonia treatment.
  • To emphasize the impact of MDR and PDR bacteria on therapeutic options and patient prognosis.
  • To underscore the necessity of global efforts to combat the spread of drug-resistant bacteria.

Main Methods:

  • Literature review on antimicrobial resistance patterns in pneumonia pathogens.
  • Analysis of clinical outcomes associated with MDR and PDR bacterial infections.
  • Synthesis of current challenges in treating resistant respiratory infections.

Main Results:

  • Increasing resistance in Streptococcus pneumoniae, Staphylococcus aureus, and gram-negative bacteria severely limits treatment choices for pneumonia.
  • Infections with multidrug-resistant bacteria correlate with higher rates of inappropriate antimicrobial therapy and adverse clinical results.
  • Treating infections caused by pandrug-resistant gram-negative bacteria presents a significant clinical hurdle.

Conclusions:

  • Antimicrobial resistance is a major threat in managing pneumonia.
  • Effective treatment strategies are increasingly restricted by the emergence of resistant bacterial strains.
  • Global collaboration is crucial to control the spread of antimicrobial resistance and improve pneumonia outcomes.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...